US Food and Drug Administration (FDA) of the United States has given final approval to Zydus Lifesciences to market Norepinephrine Bitartrate Injection USP. Norepinephrine Bitartrate is indicated for restoration of blood pressure in the adult patients suffering with acute hypotensive state. The drug will be produced at the topical injectable manufacturing of the company at Jarod, India.
According to the IQVIA data, Norepinephrine Bitartrate Injection USP had annual sales of 63.8 million dollars in the United States. The company now has 317 approval and has so far filed more than 420 ANDAs since the commencement of the filing process in the financial year 2003-2004.
Earlier, the medical dialogues team had reported that the company had received final approval from the US FDA to market Droxidopa Capsules, 100, 200, 300 mg in the United States.
The company is headquartered in Ahmedabad, India, and it stands 4th in the pharmaceutical industry of India. The company also has manufacturing facilities and research facilities spread across five states of India including Maharashtra, Himachal Pradesh, Gujarat, Goa, and Sikkim. The company also has manufacturing facilities in Brazil and the United States of America. The company is also present in 25 other emerging markets across the world.